Hormone therapy is dosed to your symptoms, not to a number on a lab report. There is no target estradiol level that means "correct," and no blood or saliva panel that tells a clinician which strength you need. The dose is chosen, then adjusted, based on whether your hot flashes, night sweats, sleep and mood actually improved and whether you are having side effects. "Lowest effective dose" is the phrase in the labels — but the operative word is effective, and being parked on a starter dose that never worked is not caution. It is undertreatment.
This page explains how dosing actually works and what the FDA labels publish. It is reference information, not instruction. Your prescriber sets and adjusts your dose. Do not start, stop, split, stretch, skip or change any dose based on anything you read here, and do not double up after a missed one.
The dose is titrated to symptom control, not to a level
This is the single most misunderstood thing about HRT, and it is misunderstood in both directions. Women assume a "hormone panel" will reveal the right dose. Companies sell that assumption back to them.
The Menopause Society's 2022 hormone therapy position statement is blunt about it: serum hormone testing is rarely needed to manage menopausal hormone therapy, and salivary and urine hormone testing to determine dosing is unreliable and not recommended. The reason is not ideology, it is lab science. Estradiol levels swing through the day and vary between assays, and no validated threshold predicts whether your hot flashes will stop. Symptoms are the endpoint, so symptoms are the measurement.
The National Academies' 2020 review of compounded "bioidentical" hormone therapy reached the same conclusion from the other side: no evidence supports using hormone concentrations to individualize doses, and there are no FDA-approved salivary or urinary tests for steroid hormone measurement used this way. Clinical guidance is to titrate on symptoms.
What that means practically: if a clinic, telehealth service or compounding pharmacy is selling you a saliva kit or a multi-hormone blood panel as the way to "personalize" or "optimize" your dose, they are selling something the evidence does not support. It does not follow that hormone testing is never appropriate — there are real exceptions, such as suspected premature ovarian insufficiency, checking a level when a patch does not appear to be absorbing, or monitoring testosterone where it is prescribed. But a routine panel to set an HRT dose is a product, not a standard of care. Our guide to menopause hormone testing covers when a test earns its keep.
What "lowest effective dose" actually means
Read the phrase literally. The label instruction is to use the lowest dose that controls your symptoms and to re-evaluate periodically — the estradiol tablet label says every 3 to 6 months. It is not "the lowest dose that exists."
Undertreatment is a real and common problem. A woman is started on a low patch or a starter tablet, comes back three months later still flashing eight times a night, and is told that this is what HRT can do. It isn't. Titration means a conversation: did it help, how much, what is left, what are the side effects, what changes now. If nothing improved and nothing was changed, that is not a dose — it is a stalled trial.
The generic oral estradiol label says it plainly: the minimal effective dose for maintenance should be determined by titration. Titration is a process, and you are entitled to it. The person who runs it is your prescriber.
What the labels publish (reference, not a recommendation)
Below are the strengths and label-published regimens for common FDA-approved estrogen products, checked against the DailyMed labels in July 2026. This is what the labels list. It is not a suggestion for you. Generics and available strengths differ by manufacturer, and the route is a clinical decision, not a preference you can act on alone.
| Route | Strengths the label lists | What the label says |
|---|---|---|
| Estradiol transdermal patch (twice-weekly generic) | 0.025, 0.0375, 0.05, 0.075, 0.1 mg/day | Applied twice weekly. The label initiates treatment of vasomotor symptoms at 0.0375 mg/day and osteoporosis prevention at 0.025 mg/day, adjusted to clinical response. Applied to the trunk (abdomen or buttocks); the label states: do not apply to the breasts. |
| Oral estradiol tablets | 0.5, 1, 2 mg | "The usual initial dosage range is 1 to 2 mg daily … adjusted as necessary to control presenting symptoms." Maintenance dose determined by titration; re-evaluate at 3- to 6-month intervals. |
| Estradiol gel, metered pump (EstroGel 0.06%) | One pump = 1.25 g gel = 0.75 mg estradiol; a 50 g pump delivers 30 metered doses | 1.25 g per day (one pump) is the single approved dose on this label. Applied in a thin layer over one entire arm, wrist to shoulder. Re-evaluated periodically. |
| Estradiol gel, single-dose packets (0.1%) | 0.25, 0.5, 0.75, 1.0, 1.25 g packets (0.25–1.25 mg estradiol) | Label starts at 0.25 g once daily on the upper thigh, adjusted up to a maximum of 1.25 g as needed; thighs alternated day to day. |
| Vaginal estradiol insert (10 mcg) | 10 mcg per insert | One insert daily for 2 weeks, then one insert twice weekly. Treats local vulvovaginal atrophy — a different job from systemic HRT, and dosed accordingly. |
Route is not cosmetic — it changes absorption, first-pass liver metabolism and some risks. That comparison lives in HRT pills vs patches vs gels, and the drug reference pages for estradiol and progesterone carry the full label detail.
The progestogen rule: the one you cannot skip
Here is the part that is not a matter of preference.
If you have a uterus and you take systemic estrogen, you must also take an adequate progestogen to protect the lining of your uterus. Estrogen stimulates the endometrium. Left unopposed, it raises the risk of endometrial hyperplasia and endometrial cancer. Skipping the progestogen, taking too little, or taking it for too few days of the cycle all leave the endometrium exposed.
The size of the effect is printed on the label. In the randomized trial cited in the progesterone prescribing information, endometrial hyperplasia occurred in 64% of women taking conjugated estrogens 0.625 mg alone over 36 months, versus 6% of women taking the same estrogen plus 200 mg of oral micronized progesterone for 12 days of each 28-day cycle. That is the gap the progestogen closes.
It is also why the FDA's November 2025 labeling action matters in a way that is often reported badly. On 10 November 2025 the agency announced it was removing the boxed-warning statements about cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy products — while explicitly not seeking removal of the boxed warning for endometrial cancer on systemic estrogen-alone products. The regulator relaxed a great deal and kept this one. Treat that as the signal it is.
Two practical corollaries:
- Low-dose vaginal estrogen is a different situation. Local products such as the 10 mcg insert are not dosed for systemic effect, and guidelines generally do not call for a progestogen alongside them. See vaginal estrogen.
- After a hysterectomy, estrogen-alone therapy is the standard approach and a progestogen is not needed. The comparison is in estrogen-only vs combined HRT.
And bleeding is information, not noise. Unexpected or persistent bleeding on HRT — and any bleeding at all after menopause — needs to be assessed, not waited out. Start with bleeding on HRT.
How a real titration goes
You cannot judge a dose in four days, and you cannot judge it from memory. What your prescriber needs is a record.
- Track before and after. Hot flashes by day and by night, wake-ups, mood, joint pain, brain fog, libido. Two lines a day is enough.
- Give it a fair window. Vasomotor symptoms usually respond within weeks; many clinicians reassess at roughly 8 to 12 weeks. Local vaginal symptoms take longer — often several weeks to a few months for full effect.
- Report side effects specifically. Breast tenderness, nausea, headaches, unexpected bleeding. These are titration data, not complaints.
- Do not self-adjust. Do not cut patches, add pumps, skip days to "give your body a break," or double up to catch up after a missed dose. If you miss one, follow the leaflet that came with your product and call your pharmacist. Take what you were prescribed, and ask before you change it.
Our menopause doctor report turns that tracking into a one-page summary you can hand over, and questions to ask your doctor about HRT gives you wording for the follow-up appointment where the dose actually gets changed.
What about cost and coverage?
We will not quote you a price, because any figure we published would be wrong for most readers and stale within months. What you pay depends on your plan's formulary tier, your deductible, whether the product is generic or brand, and whether your pharmacy's cash price undercuts your own copay — which it sometimes does.
What is stable enough to be useful: generic oral estradiol and generic estradiol patches sit on the cheapest tiers of most formularies, while brand-name gels, brand vaginal inserts and brand combination products are where the bills get painful. Coverage of vaginal estrogen and of combination products varies a lot between plans. Before you assume a product is unaffordable, ask three questions — is there a generic of this exact product, what tier is it on my plan, and would a different approved route cost less. That is a prescriber-and-pharmacist conversation, and it is worth having: cost is one of the most common reasons women quietly stretch doses or stop treatment altogether. Stretching a dose to make a box last longer is not a cost-saving strategy. It is an untreated month, and it is a conversation you are allowed to have out loud.
The short version
Dose is set against symptoms, not against a lab value. Panels sold to "optimize" your dose are marketing, not medicine. The labels publish standard strengths, and a prescriber picks among them and then adjusts — that adjustment is the whole point, and being left on an ineffective starter dose is a failure of the process, not the safest version of it. And if you have a uterus and take systemic estrogen, adequate progestogen is not optional.
This article is health information, not medical advice, and nothing in it is a dosing instruction. VidaBeacon has no financial relationship with any hormone therapy manufacturer, pharmacy or telehealth service, and this page contains no affiliate links.
